Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
IMFINZI (durvalumab), a human monoclonal antibody targeting PD-L1, is a key component of the CASPIAN regimen, which incorporates etoposide and either carboplatin or cisplatin for patients with ES-SCLC. By binding to PD-L1, IMFINZI inhibits its interaction with PD-1 and CD80, helping to restore T-cell function and facilitate immune-mediated recognition of tumour cells. This mechanism addresses the immunosuppressive environment commonly observed in ES-SCLC, which can limit the ability of the immune system to mount an effective antitumour response.3
Adapted from IMFINZI Summary of Product Characteristics.3
APC – antigen-presenting cell; CD80 – cluster of differentiation 80; PD-1 – programmed cell death 1; PD-L1 – programmed death-ligand 1.
Discover more about the CASPIAN study design and efficacy outcomes
Get to know the CASPIAN safety profile
Learn more about the dosing details in the CASPIAN Regimen
GB-68889 | DOP: August 2025
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
GB-74216| DOP : February 2026
